| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.2M | -12.3% | -20.4% |
| SG&A Expense | $1.2M | -47.2% | -26.4% |
| Operating Income | -$3.3M | +28.5% | +22.6% |
| Net Income | -$3.8M | +18.7% | +12.0% |
| EPS (Basic) | -$5.00 | -2841.2% | -306.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.1M | -18.1% | -25.9% |
| Current Assets | $1.7M | -16.6% | -10.6% |
| Total Assets | $3.6M | -6.9% | -8.8% |
| Current Liabilities | $2.6M | +4.7% | +13.8% |
| Total Liabilities | $2.8M | — | — |
| Stockholders' Equity | $768K |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.2M | — | — |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $10.7M | — | — |
| -44.8% |
| -53.9% |